Millipore Sigma Vibrant Logo
Attenzione: Ci siamo trasferiti. Non è più possibile acquistare i prodotti Merck Millipore nel sito MerckMillipore.comPer saperne di più

371830 GPR40 Antagonist, GW1100 - CAS 306974-70-9 - Calbiochem

371830
Purchase on Sigma-Aldrich

Panoramica

Replacement Information

Tabella delle specifiche principali

CAS #Empirical Formula
306974-70-9C₂₇H₂₅FN₄O₄S

Products

Numero di catalogoConfezionamento Qtà/conf
371830-10MG Bottiglia di vetro 10 mg
Description
OverviewA cell-permeable pyrimidinylmethyl-pyrimidinone compound that acts as potent, reversible and non-competitive GPR40 antagonist. Selectively blocks GPR40-mediated intracellular Ca2+ release stimulated by GPR40 Agonist GW9508 (Cat. No. 371706) and linoleic acid (pIC50 of 5.99 in GPR40 expressing HEK293 cells) with no effect on GPR120-mediated activation. Shown to significantly reverse glucose-induced insulin secretion potentiated by GW9508 and only partially reduce linoleic acid effect in MIN6 cells.
Catalogue Number371830
Brand Family Calbiochem®
Synonyms1-(4-Ethoxycarbonylphenyl)-2-(4-fluorobenzylthio)-5-(2-ethoxy-5-pyrimidinylmethyl)-4-pyrimidinone, SB376752
References
ReferencesStoddart, L.A., et al. 2007. Mol. Pharmacol. 71, 994.
Briscoe, C.P., et al. 2006. Br. J. Pharmacol. 148, 619.
Product Information
CAS number306974-70-9
FormWhite powder
Hill FormulaC₂₇H₂₅FN₄O₄S
Chemical formulaC₂₇H₂₅FN₄O₄S
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥97% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numero di catalogo GTIN
371830-10MG 04055977213478

Documentation

GPR40 Antagonist, GW1100 - CAS 306974-70-9 - Calbiochem MSDS

Titolo

Scheda di sicurezza (MSDS) 

GPR40 Antagonist, GW1100 - CAS 306974-70-9 - Calbiochem Certificati d'Analisi

TitoloNumero di lotto
371830

Riferimenti bibliografici

Panoramica delle referenze
Stoddart, L.A., et al. 2007. Mol. Pharmacol. 71, 994.
Briscoe, C.P., et al. 2006. Br. J. Pharmacol. 148, 619.
Scheda tecnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision10-August-2012 JSW
Synonyms1-(4-Ethoxycarbonylphenyl)-2-(4-fluorobenzylthio)-5-(2-ethoxy-5-pyrimidinylmethyl)-4-pyrimidinone, SB376752
DescriptionA cell-permeable pyrimidinylmethyl-pyrimidinone compound that acts as potent, reversible and non-competitive GPR40 antagonist. Selectively blocks GPR40-mediated intracellular Ca2+ release stimulated by GPR40 Agonist GW9508 (Cat. No. 371706) and linoleic acid (pIC50 of 5.99 in GPR40 expressing HEK293 cells) with no effect on GPR120-mediated activation. Shown to significantly reverse glucose-induced insulin secretion potentiated by GW9508 and only partially reduce linoleic acid effect in MIN6 cells.
FormWhite powder
Intert gas (Yes/No) Packaged under inert gas
CAS number306974-70-9
Chemical formulaC₂₇H₂₅FN₄O₄S
Structure formulaStructure formula
Purity≥97% by HPLC
SolubilityDMSO (50 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesStoddart, L.A., et al. 2007. Mol. Pharmacol. 71, 994.
Briscoe, C.P., et al. 2006. Br. J. Pharmacol. 148, 619.